Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japan, Singapore to Cooperate in the Field of Biomaterials
March 4, 2002
- Precautions for 4 Drugs Including Acarbose Revised
March 4, 2002
- Novo Nordisk Offers Grant for Research on Low Stature
March 4, 2002
- Administration Restrictions on IFN Lifted
March 4, 2002
- Abolition of Long-term Admission Fees from Insurance Coverage Hits Hospitals:Dr Itouji of JMA
March 4, 2002
- Korosho Calls on Medical Professionals to Cooperate in Immediate PMS
March 4, 2002
- Bungyo Rate Increases to 44.9% in October 2001
March 4, 2002
- REGULATORY NEWS IN BRIEF
March 4, 2002
- AJHA Holds 1st Seminar on TQM
March 4, 2002
- BULLETIN
March 4, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 4, 2002
- Spin-off of Manufacturing Plants to Increase: PAL Revision
March 4, 2002
- 12,558 Drugstores Operated by 590 Companies: JACDS Survey
March 4, 2002
- Study Group Proposes Proper Drug Distribution System
March 4, 2002
- Taisho Appeals against Daikoku
March 4, 2002
- Manufacturers' FTC Issues Guide Regarding Entertainment
March 4, 2002
- Additional Premiums to Be Introduced in Medical Material Pricing System
March 4, 2002
- Kyowa Hakko to Transfer Its Liquor Business to Asahi Breweries
March 4, 2002
- Medical Devices to Be Re-priced to Reduce Domestic, Foreign Price Gaps
March 4, 2002
- REGULATORY NEWS IN BRIEF
February 25, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…